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Chronic kidney disease (CKD) is a set of pathophysiological reactions that impact the 
functionality of the kidney. The association between microvascular disease (MVD) and 
CKD as it relates to diabetes is important to the evaluation of organization effectiveness 
in hospital services planning as well as improving health outcomes. The purpose of this 
quantitative, cross-sectional study was to determine if there is an association between 
MVD and CKD severity in persons with diabetes. Using the socioecological model, the 
association between gender, age group, cigarette smoke, cigarette smoke frequency, 
alcoholic drink, alcoholic drink frequency, hypertension, albumin-to-creatinine ratio 
(ACR) severity, cholesterol, sickling (i.e. persons with sickle cell disease),and MVD was 
examined. Across-sectional data analysis, using secondary data from 2013 to 2017 (N = 
775) in the Grenada medical records department, was used to identify associations of 
CKD status in persons with diabetes over the age of 16 years old. The relationship 
between the study predictors and the outcome variable was analyzed using chi-square 
tests and binomial logistic regression. The key findings showed drinking and 
hypertension were the only significant predictors of CKD severity. The social change 
implications of  this study will not only benefit health care professionals but also the 
community by assisting in the, enhancement of national guidelines and public health 
policy, and the implementation of programs aimed to improving risk factors that have 
been shown to reduce CKD outcomes in Grenada.  
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Section 1: Foundation of the Study and Literature Review 
Introduction 
Microvascular disease (MVD) results in the narrowing of small vessels within the 
body, impacting the functionality of the body system (Beckman, J.A., Duncan, M.S., 
Damraven, S.M., … Freiberg, M.S., 2019). The primary contributing factor of MVD is 
exposure of the tissues to chronic hyperglycemia (Diabetes.co.uk, 2018).  In persons with 
Type 2 diabetes (T2DM), MVD has been shown to be associated with a higher risk of 
macrovascular events (Mohammedi et al., 2017). Additionally, persons with T2DM that 
present with MVD have an increased risk of cardiovascular morbidity and mortality when 
excluding pre existing risk factors for cardiovascular disease (Brownrigg et al., 2016). 
According to the Centers for Disease Control and Prevention’s (CDC; 2014b) National 
Diabetes Statistics Report, MVD can be reduced through proper control of blood sugar 
levels; however, left untreated, MVD can lead to various complications as it relates to 
diabetes, including diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy. 
Nephropathy is the damaging or disease of the kidney, and in diabetic nephropathy that 
damage is due to complications related to a person having diabetes (Gross, J.L., Silveiro, 
S.P., Canani, L.H., Caramori, M.L., & Zelmanovitz, T.,2005). In severe cases, this can 
lead to kidney failure and organ transplantation; however, kidney damage does not occur 
in all cases of diabetic persons (American Diabetes Association, 2015a). Nephropathy 
can lead to end stage renal disease (ESRD), which in turn can lead to persons needing 
dialysis and kidney transplantation (Moore et al., 2009). The contributing factors that can 
lead to ESRD include the development of hypertension and a decrease in glomerular 
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function (Martínez-Maldonado, M., 1998). According to the National Institute of 
Diabetes and Digestive and Kidney Diseases (2016), more than 661,000 Americans had 
kidney failure and compared to Caucasians, ESRD is about 3.7 times more prevalent in 
African Americans, 1.4 times greater in Native Americans, and 1.5 times higher in Asian 
Americans. Retinopathy is a condition that affects the retina; decreases vision; and over 
time, if left uncontrolled, can lead to blindness. In the United States, diabetic retinopathy 
is one of the leading causes of blindness among 25- to 74-year-olds (CDC, 2014a; 
Whitaker, 2001). Finally, a complication of MVD is neuropathy, which impacts nerves of 
the individual. Among diabetic polyneuropathy persons, 20% to 30% suffer from 
neuropathic pain (Tesfaye et al., 2011). Common symptoms can vary from a reduction in 
pain sensations to changes in pressure sensations, which can not only lead to lower limb 
injuries but also an increased risk of lower limb amputations (Hicks, C.W. & Selvin, E., 
2019).  
This study was designed to look at the association between MVD and chronic 
kidney disease (CKD) in persons with T2DM within Grenada. In this study, I examined 
factors that influence health outcomes related to CKD, T2DM, and MVD as well as made 
recommendations that may assist in improving national chronic health conditions. 
Implementation of the findings of this study may improve the effectiveness of primary 
health programs in Grenada because the findings provide evidence for the planning, 
decision-making, and implementation of health policies. The study may also be used as a 
resource for further investigation and strategic planning of other chronic disease concerns 
in Grenada.  
3 
 
In this section of this dissertation, I elaborate on the problem statement and clarify 
the purpose of the study. This is followed by a presentation of the research questions and 
hypotheses, theoretical foundations for the study, nature of the study, and literature 
search strategy. The rest of the section is devoted to an extensive literature review in 
which major concepts are defined; the assumptions made in the study are itemized; and 
the scope, limitations, and delimitations of the study are described. 
Problem Statement 
CKD is a condition that does not occur in isolation(i.e., does not occur due to one 
particular issue) but instead is a range of pathophysiological reactions linked to changes 
in the functionality of the kidney as well as a continued decline of its glomerular filtration 
rate (GFR; Ferguson et al., 2012).According to the Kidney Disease: Improving Global 
Outcomes Chronic Kidney Disease Workgroup(2012) CKD is defined as when the 
structure and functionality of the kidney presents this decline for more than 3 months and 
impedes an individual’s health. Abnormal kidney function occurs when the GFR is less 
than 60 ml/min/1.73m2 (Ferguson et al., 2012). The severity of CKD is determined by 
the stage at which the disease has progressed. These stages increase in severity from 
Stage 1 to Stage 5, with Stages 3–5 being considered the most dangerous and leading to 
ESRD, dialysis, or even death (Thomas, R., Kanso, A., &Sedor, J.R., 2008). It is 
estimated that the worldwide prevalence of CKD is between 8% and 16% and 11.5% in 
the United States (Levey & Coresh, 2012). Within the Caribbean, however, the exact 
prevalence and incidence of CKD and MVD are not fully known due to incomplete or 
inaccurate data collection within the Organization of Eastern Caribbean States (OECS), 
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which includes the countries of Grenada, Commonwealth of Dominica, Antigua, St. 
Lucia, St. Vincent and the Grenadines, and St. Kitts and Nevis.  
Among OECS countries, chronic noncommunicable diseases (CNCDs) continue 
to plague the region (Crews et al., 2017). Non communicable diseases (NCDs), including 
diabetes, stroke, CKD, heart disease, and hypertension, are among the significant 
contributors to over half of deaths among members of the OECS (Caribbean 
Epidemiology Centre, 2000). Per the International Diabetes Federation (IDF), the global 
prevalence of diabetes mellitus (DM)is 8.3% of the population, with the Caribbean 
having an overall prevalence of approximately 9%,which is responsible for 13.8% of all 
adult deaths in the region (Bennett et al., 2015). The Pan American Health Organization 
(PAHO) says that within the Caribbean region, DM affects an estimated 10% to 15% of 
the adult population and accounts for most premature deaths (PAHO, 2012). 
Persons with renal impairments (i.e., CKD Stages 3–5) not only have an increased 
risk of MVD but also a higher likelihood of aortic, cerebrovascular and peripheral 
vascular disease (Ooi et al., 2011). Additionally, CKD patients have an increased chance 
of developing lacunar infarcts, and those over the age of 55 years old make up almost 
70% of dialysis patients with varying degrees of cognition impairments that are of 
microvascular origin (Soyibo, Roberts, & Barton, 2011). Persons from an African-
Caribbean background have been found to have not only a higher prevalence of diabetes 
and renal failure, but also worse overall outcomes as compared to other ethnic groups 
within the United Kingdom (Brown, Avis, & Hubbard, 2007).  
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Due to the increasing numbers of persons within the Caribbean having diabetes 
and developing either CKD or ESRD, it is essential to see if any additional links may be 
leading to these disproportionate numbers. Another link that could be evaluated, as it 
relates to CKD and diabetes, is to look at the MVD. MVD is defined as an injury to small 
blood vessels in the body, including capillaries, resulting in such issues as nephropathy, 
retinopathy, and neuropathy (CDC, 2014a). However, there have not been studies on the 
relation of MVD to CKD patients with diabetes in the region (Ezenwaka et al., 2008; 
Ezenwaka et al., 2016; Graciolli et al., 2017); therefore, I conducted this study to fill the 
gap in the literature. 
Per the Caribbean renal registry, DM and hypertension are the leading causes of 
CKD and ESRD (Soyibo et al., 2011). Although many have studied diabetes, CKD, 
ESRD, and their prevalence, there has been little research conducted on MVD and its 
relationship to CKD severity in individuals with diabetes, specifically in Grenada. The 
extant literature includes studies specifically related complications of CKD/ESRD (i.e., 
anemia and mineral bone disease) and its related complications (i.e., obesity, 
hypertension, and dyslipidemia).  
Purpose of the Study 
The purpose of this quantitative, exploratory study was to determine the 
association between MVD and CKD severity in individuals with diabetes in Grenada. In 
this study, I also sought to look at the organizational factors of the socioecological model 
(SEM) of health and its impact on CKD outcomes. This was not an intervention study but 
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rather an exploratory, cross-sectional study to set the groundwork for potential further 
studies on CKD severity on diabetes patients on the island. 
Research Questions and Hypotheses 
RQ1: Is there an association between MVD and CKD severity among diabetes 
patients in Grenada with or without hypertension, when controlling for age, 
gender, glycated hemoglobin (A1C), body mass index (BMI), alcohol use, and 
smoking? 
H01: There is no statistically significant association between MVD and 
CKD severity among diabetes patients in Grenada with or without 
hypertension when controlling for age, gender, A1C, BMI, alcohol use, 
and smoking. 
HA1: There is a statistically significant association between MVD and 
CKD severity among diabetes patients in Grenada with or without 
hypertension when controlling for age, gender, A1C, BMI, alcohol use, 
and smoking. 
RQ2: What is the significance between prevalence of MVD and CKD severity 
among patients in Grenada with diabetes with or without hypertension when 
controlling for age, gender,A1C, BMI, alcohol use, and smoking? 
H02: There is no significance between prevalence of MVD and CKD 
severity among patients in Grenada with diabetes with or without 




HA2: The prevalence of MVD is ≥ 50% of CKD patients in Grenada with 
diabetes with or without hypertension when controlling for age, gender, 
A1C, BMI, alcohol use, and smoking. 
Theoretical Foundation for the Study 
I used SEM as the theoretical framework of this study to explore the 
environmental risk factors that may increase a person’s possible development of MVD as 
it relates to CKD severity in persons with diabetes within Grenada. The SEM is a health 
promotion approach that looks at some broad variables that influence health, whether for 
the good or bad (Robinson, 2008). The SEM is made up of five factors: individual, 
interpersonal, community, organizations, and or policy/enabling environmental factors 
(Green, Richard,& Potvin, 1996; Stokols, 1996;see Figure 1). The United Nations 
Children’s Fund (UNICEF) identifies these factors include individual, interpersonal, 
community, organizations, and policy /enabling environmental factors. Individual factors 
are an individual’s knowledge, attitudes, and behaviors that impact their health, including 
but not limited to age, gender, ethnicity, and sexual orientation (UNICEF, 2009). 
Interpersonal factors are the social networks and social support systems that may 
influence a person’s behaviors (UNICEF, 2009). Community factors are the association 
among the organizations and informational networks within a specific location, including 
the local environment, villages, community leaders, and businesses (UNICEF, 2009). 
Organizational factors are those that impact the effectiveness of services provided and 
may hinder the health of a group or individual (UNICEF, 2009). Finally, policy/enabling 
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environmental factors are local, state, national, and international laws and policies that 
impact the health of an individual or a group of persons (CDC, n.d.; UNICEF, 2009). 
 
Figure 1.Social ecological model diagram. Source: 
http://www.cdc.gov/violenceprevention/overview/social-ecologicalmodel.html 
 
 In this dissertation, I focused on the organizational factors of the SEM. The 
organizational factors (i.e., the rules, regulations, policies, and informal structures) can 
either promote or constrain health behaviors (Robinson, 2008). By understanding the 
current health situation related to MVD, CKD, and diabetes among the Grenadian 
population, along with the health organizational structure within the country, the 
groundwork for improving the healthcare system can be better laid. Using this factor of 
the SEM in this study, helped me better understand any potential organizational barriers 
to the treatment and life expectancy variation between persons in Grenada with this 
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disease as compared to the Western world. I conducted this study through the collection 
of secondary data, mainly mortality and morbidity rates of persons living with CKD and 
diabetes and compared these rates to those with MVD along with CKD and diabetes. 
Collecting and comparing this information as well as information related to the cost of 
services, cost of living, and the availability of specialists related to this disease provided 
the groundwork for future work in developing policies and educational assistance for 
healthcare professionals to decrease the mortality and morbidity rates as it relates to this 
disease. The findings of this study also have the potential to provide much-needed 
information on health promotion initiatives as well as for the continued education of 
medical staff and the procurement of any needed specialists for this field. 
Nature of the Study 
I used a quantitative, cross-sectional design to MVD to CKD severity in 
individuals with diabetes among Grenadians. The secondary data used in this analysis 
came from the sampling of 2016 medical records. In-depth interviews, questionnaires, 
and focused groups were not used in this study because the primary focus was on the 
potential severity of this CNCD in Grenada. The independent variables in the study were 
MVD and diabetes, the dependent variable was CKD severity, and the controls were age, 
gender, smoking, and weight. 
Literature Search Strategy 
I used the following databases to locate literature for this study: Walden 
University Library and Walden Library Books, PubMed, CINAHL Plus with Full Text, 
MEDLINE with Full Text, Dissertations & Theses, and Dissertations& Theses at Walden 
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University, ProQuest Central, Science Journals, and Science Direct. Good Scholar, 
Google, Walden Library Search, World Health Organization (WHO), UNICEF, PubMed, 
and ProQuest search engines were also used. The following keyword search terms were 
used: Type 2 diabetes, diabetes mellitus, CKD, chronic kidney disease, microvascular 
disease, risks for microvascular disease, Caribbean, risks for CKD, diabetes in Grenada, 
CKD in the Caribbean, social ecological model, IDF, UNICEF report, WHO report, 
NDHS, SEM, and CDC reports. 
Although I had an open-ended search for literature, emphasis was placed on 
publications spanning a period of 5 years (i.e., 2013–2018) for this study. I also placed 
emphasis on peer-reviewed primary publications within the period under review. In 
addition, national documents, WHO, CDC, and UNICEF periodicals and reports were 
used to augment the literature review. Some seminal literature like that on the SEM as 
well as some critical publications on prevalence of CKD, diabetes, and its related risk 
factors within the Caribbean region was used. Finally, a few doctoral studies and 
dissertations from the Walden University Library were also reviewed. 
Literature Review Related to Key Variables and/or Concepts 
Population 
According to the Index Muni (2018), as of 2017, it is estimated the population of 
Grenada to be about 111,724, with 24% being less than 15 years of age, just 10% over the 
age of 65, and a median age of 31.5 years. Of this, 35.7% lived in urban communities; the 
total sex ratio of male to females is 1.03, and as of 2016, a birth rate of 15.5 per 1,000 
population and 9.7 deaths per 1,000 live births per year (Index Muni, 2018). With a gross 
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national income per capita of $14,700, Grenada spends about 6.1% of the gross domestic 
product on health (Central Intelligence Agency, 2017; WHO, 2015). Grenadians have a 
life expectancy at birth for males and females of 71 and 76 years old, respectively (WHO, 
2015).  
Grenada has about five different ethnic groups who speak roughly five different 
languages and dialect; however, English is the official language with French Patois, 
Spanish, Mandarin, and Indian Hindi being the dominant local languages (Central 
Intelligence Agency, 2017). Christianity is the predominant religious belief, with some 
being Roman Catholic and the majority being Protestant (The World Factbook, 2018).   
According to Health Grove (2013b), the annual mortality rate per 100,000 persons 
related to DM increased by 57.5% in Grenada since 1990. From 2005 to 2016, the 
incidence of diabetes dropped by 2.7% from 2005 to 2016; however, it not only remains 
the third leading cause of death in the country but also the third leading cause of 
premature deaths with an increase of 0.4% during the same period (Institute for Health 
Metrics and Evaluation, 2016). However, CKD is the leading cause of disability-adjusted 
life years and the fifth leading cause of death in 2016 (Institute for Health Metrics and 
Evaluation, 2016).  
Physiology of Chronic Kidney Disease 
CKD is characterized as a condition that damages the kidneys and decreases its 
functionality (National Kidney Foundation, 2017). CKD can be quantified by a high 
measure of the GFR for more than 3 months (Thomas, Kanso, &Sedor, 2008). According 
to the U.S. National Kidney Foundation, Kidney Disease Outcomes Quality Initiative, 
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CKD is defined as damage to the kidney or GFR lower than 60 ml/min per 1.73 m2 for 3 
months or longer (Jha et al., 2013). The main contributors to CKD in individuals are 
diabetes and hypertension; however, any health condition that damages the kidneys can 
lead to CKD (CKD, 2019). Within the Caribbean, as of 2013, the significant risk factors 
for CKD include low GFRs, high systolic blood pressure, high fasting plasma glucose, 
high body mass index, and dietary risks (Health Grove, 2013a). This CNCD is a global 
issue impacting persons from all income levels and various income countries; however, 
the incidence, prevalence, and progression of CKD vary per country (Webster, Nagler, 
Morton, & Masson, 2016). Per Health Grove (2013a), the annual mortality rate for CKD 
within the Caribbean is 18.39 per 100,000 people, which is an 87.1% increase from 1990.  
The kidney is a vital organ within the body. Some of the functions of the kidney 
include: “excretion of waste, acid-base regulation, body water and electrolytes, 
detoxify/metabolize drugs/hormones, regulate blood pressure and endocrine system” 
(Gattone, 2007, A-2 ). Due to the gradual progression of kidney deterioration, many 
persons are asymptomatic until kidney damage irreversible (Pradeep, A.M., 2020).As the 
kidney begins to decline in functionality; complications can lead from CKD to ESRD 
(Thomas et al., 2008). When this begins to occur, it is classified by way of the National 
Kidney Foundation’s Kidney Disease Outcomes Quality Initiative from Stage 1 to Stage 
5.  The premise of Kidney Disease Outcomes Quality Initiative is to establish guidelines 
for establishing universal best practices for clinical kidney disease, including (a) defining 
CKD and classify its stages despite its underlying cause, (b) evaluating laboratory 
measurements of assessing clinical kidney disease, (c) associating kidney function levels 
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with CKD complications, and (d) determining risk of kidney loss of function and the 
development of cardiovascular disease (Levey et al., 2003). These stages are clinically 
defined by laboratory evaluations as follows: Stage 1-normal  eGFR ≥90 mL/min per 
1.73m2; Stage 2-  eGFR between 60 to 89 mL/min per 1.73m2; Stage 3-  eGFR between 
30 to 59 mL/min per 1.73 m2; Stage 4- EGFR between 15 to 29 mL/min per 1.73 m2; and 
Stage 5- EGFR of <15 mL/min per 1.73m2 or ESRD (Chapter 1: Definition and 
classification of CKD,2013). 
Physiology of Diabetes 
DM orT2DMis a metabolic disorder characterized by the ineffective distribution 
of insulin within the body, also known as hyperglycemia (American Diabetes 
Association, 2013). Insulin, the energy vehicle within the body that moves sugar into the 
cells, is produced in the pancreas (Cologne, Germany: Institute for Quality and efficiency 
in health care, 2018).When the pancreas begins to have difficulty accurately producing 
insulin, it can lead to Type 1 diabetes, or juvenile diabetes, which is more commonly 
found in children (Fonseca, 2006). In contrast, in T2DM, the body has sufficient insulin 
in the body but is not able to utilize it efficiently to lower the blood glucose levels 
(Fonseca, 2006).Where T2DM deals with the utilization of insulin in the body, Type 1 
diabetes deals with the lack ofa deficiency of insulin, usually occurring within children 
(American Diabetes Association, 2009). Another form of diabetes can occur during 
pregnancy, which can increase a woman’s chances of developing T2DM later in life 
(Kim, Newton, &Knopp, 2002). In this study, I focused on T2DM.  
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Persons that are diagnosed with diabetes are usually of increased age, 
overweight/obese, and with decreased physical activity; genetics also can play a 
significant role in the development of diabetes (Pulgaron, E.R. & Delamater, A.M., 
2014). The bodies’ inability to efficiently utilize insulin within the cells is known as 
insulin resistance (Wilcox, G., 2005). Insulin resistance has been said to be responsible 
for health concerns, including obesity, hypertension, triglyceride and cholesterol 
abnormalities, polycystic ovarian syndrome, and increased heart disease risk (Whitaker, 
2001). T2DM left untreated or managed can lead to hyperglycemia, resulting in the most 
diabetic-related physical complications (Ramteke, P., Deb, A., Shepal, V., & Bhat, M.K., 
2019). This increased level of glucose within the body leads to a build-up of sorbitol, 
which has been shown to be linked to nerve and eye damage (Whitaker, 2001). 
Unfortunately, this form of diabetes is many times left untreated for years, and when 
discovered, the person has extremely high blood glucose levels; nerve, eye, and kidney 
damage, and other organs may have been compromised (Department of Health and 
Human Services, 2015). All of this damage could be mitigated through either a fasting 
blood glucose test, which looks at the amount of glucose in an individual’s body when 
fasting for 8 hour or an A1C test, which looks glucose average within a 3-month period 
(Sherwani, S.I., Khan, H.A., Ekhzaimy, A., Masood, A., & Sakharkar, M.K., 2016 ). A 
diagnostic fasting blood glucose reading of 70–110 mg/dl is within reasonable limits, and 
values great than 126 mg/dl can suggest a person has diabetes, which would be followed 
up with an A1C test for confirmation(American Diabetes Association, 2016). Gaining a 
better understanding of the physiology of diabetes and its contributing factors will not 
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only reduce the risk of developing diabetes but also decrease its prevalence within the 
region and around the world.  
Prevalence of Type 2 Diabetes 
As of 2015, 30.3 million or 9.4% of people in the United States are diagnosed 
with diabetes, and of these, 7.2 million are undiagnosed or unaware they have diabetes 
(ADA, 2015b). Globally, there has been an increase in diabetes from 108 million or 4.7% 
in 1980 to 422 million or 8.5% as of 2014, indicating that diabetes has become an 
increasing global threat both to individuals as well as health systems (WHO, 2017). It is 
estimated that by 2030, the world prevalence of diabetes will increase from 6.4% of the 
population or 285 million adults from 2010 to 7.7% or 439 million by 2030 (Shaw, J.E., 
Sicree, R.A., &Zimmet, P.Z., 2010). Fonseca (2006) estimated that by 2050, the number 
of people in the United States diagnosed with diabetes will be 39 million (a 225% 
increase) and prevalence between 4.4% to 9.7% (a 120% increase from previous 
estimates). The diabetes prevalence increase has affected 69% of developing countries 
and 20% of developed countries (Shaw, Sicree, &Zimmet, 2010).It is also estimated that 
over 70% of cases in the next 20 years will come from developing countries, with most 
persons affected being between the ages of 45 and64 years old  (Wild, Roglic, Green, 
Sicree, & King, 2004).According to the Macro Economy Meter (2013),Grenada is ranked 
61st as it relates to diabetes and the prevalence of diabetes for populations aged 20 to 79 
years is 9.44% as compared to countries such as Bosnia and Herzegovina, Portugal, 
Sudan, Iraq, Chile, Tunisia, Cyprus, Brazil, South Africa, and the United States. 
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Some of the major influencers on the increase of diabetes prevalence are an 
increasingly aging population among seniors 65 years and older, ethnicity, family history, 
being obese, socioeconomic status, increased age, sedentary lifestyles, place of residence, 
and having diets rich in fats; these factors have been shown to increase the prevalence of 
diabetes both in the U.S. and around the world (ADA, 2013; CDC, 2013; Jain & Saraf, 
2010). According to the CDC (2012a), an estimated 25.9% or 12 million of seniors in the 
United States have T2DM. Ethnic groups are the hardest affected by T2DM and seem to 
have a higher predisposition to the development of this disease. The ethnic groups in the 
United States most impacted are American Indians/Alaska Natives (15%), Asian 
Americans (9.0%), non-Hispanic Blacks (13.2%), and Hispanic Americans (12.8%) as 
compared to Non-Hispanic Whites(7.6%;CDC, 2014a). Within the Caribbean, it has been 
found that there is a higher prevalence of diabetes among adult Black populations, 
affecting about 1 in 5 persons, and increasing morbidity and mortality rates (Hennis et al., 
2002).  
Prevalence of Chronic Kidney Disease 
As industrialization has changed the face of the known world, there has been a 
shift in the focus of the health field from infectious diseases to CNCDs. One such change 
includes the leading causes of morality. Diseases of the kidney, overtime, have not only 
become a leading contributor of mortality rates but also are steadily reaching epidemic 
magnitudes within first-world countries (Eknoyan et al., 2004). It is estimated that 8%–
16% of persons in the world are affected by CKD (Jha et al., 2013).According to the 
2010 Global Burden Disease study, in 1990 CKD was ranked 27thon the list of causes for 
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the total number of global deaths; however, its ranking had increased to 18th in 2010 with 
an annual death rate of 16.3 per 100,000 (Lozano et al., 2013). Kidney disease is 
attributed to more deaths than prostate or breast cancer, and in 2013, it was reported that 
more than 47,000 Americans died from it (Xu, Murphy, Kochanek, &Bastain, 2013). 
Within the United States, CKD occurs in 14% of the general population (NIDDK, 2016). 
The NIDDK (2016) found that more than 661,000 Americans currently have kidney 
failure, of which 468,000 are on dialysis, and an estimated 193,000 are living with 
operational kidney transplants.  
Though within the United States CKD can affect anyone, it does not impact each 
race equally. The CDC (2012b) found that African Americans (17.01%) and Mexican 
Americans (15.29%) were more likely to have CKD than European Americans (13.99%). 
Not only is there a variation in prevalence among races but also by gender. Women are 
more likely to be diagnosed with CKD Stages 1–4 then men, 15.93% and 13.52%, 
respectively (CDC, 2012b).  
Additional factors that may influence the prevalence of CKD are the following 
four main risk factors: susceptibility, initiation, progression, and end-stage (Taal, M.W. 
& Brenner, B.M., 2006). Susceptibility factors are those factors that increase a person’s 
chances of developing kidney damage; this includes older age, family history, reduction 
of kidney mass, low birth weight, low income or education, and ethnicity (Levey et al., 
2003). The second factor, initiation factors, are those that directly start the process of 
kidney damage, would include diabetes, high blood pressure (BP), autoimmune diseases, 
systemic infections, urinary tract infections, urinary stones, lower urinary tract 
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obstruction, or drug toxicity (Levey et al., 2003). The third contributing factor is a 
progression of the disease; these are causes that worsen the kidney damage and factors 
that decrease the functionality of the kidney after the commencement of kidney damage, 
some examples include high BP, poor glycemic control in diabetes, smoking, and 
elevated protein urea (Levey et al., 2003). Finally, end-stage factors are those that 
increase persons’ morbidity and mortality rate within kidney failure; this would include 
low dialysis dose, late referral to care, low serum albumin levels, anemia, or temporary 
vascular access (Levey et al., 2003). However, little is known about the actual prevalence 
of CKD within the Caribbean. 
Risk Factors for Type 2 Diabetes 
The prevalence of T2DM in North America and the Caribbean is estimated at 
12.9% (IDF, 2015). Within Grenada, the national prevalence of diabetes among adults is 
10.3% of persons age 20-79, which is 6.9 in every 1,000 persons (IDF, 2015). There is a 
multitude of various factors that have been found to contribute to the development of 
T2DM. Per the CDC (2012a) persons having a low socio-economic status (SES) have a 
higher risk of developing T2DM than those of higher economic status. A major 
contributing risk factor to its development is family history (Cheng et al., 2012). Studies 
have shown that even when factoring in socioeconomic and behavioral factors, Blacks 
were twice as more likely to develop T2DM than their White counterparts (Brancati et 
al., 2000). As the level of education decreases, as well as income and SES, there was 
found to be an increased risk of T2DM, according to the prospective Black Women’s 
Health Study (Krishnan et al., 2010). Studies have also shown that there is a link between 
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low SES and increased T2DM. The potential reasons for this link include lack of 
resources, diminished accesses to healthcare, lower levels of income, education and 
physical inactivity, and postponement of medical care and inadequate dietary options 
within available income (Robbins, Vaccarino, Zhang, &Kasl, 2005; Williams & Jackson, 
2005).Alternatively, as education and income increased the same study found no 
difference in the development of T2DM among women (Conen et al., 2011). Another 
contributing risk factor would obesity and weight of the individual. These findings were 
challenged by a study by Lee et al. (2011), which found that low SES was not responding 
to the increased rate of T2DM among the African American community. In short, a 
person’s increase of education and income did not prevent their development of diabetes. 
These risk factors may have been found to contribute to the risk of development of 
T2DM, but it is not always quite that simple. 
According to a study by the United States Agency for International Development 
(USAID) in collaboration with Johns Hopkins School of Public Health, within the Latin 
American and Caribbean (LAC) region about half of all years lost to life are attributed to 
NCDs (Anderson et al., 2009). Among Black Barbados Caribbean nationals, there is a 
noticeably high prevalence of diabetes as compared to other ethnic groups within the 
country, affecting an estimated 1 in 5 people and increasing mortality and morbidity rates 
(Henniset al., 2002). The issues of diabetes and its related factors, as it relates to the 
prevalence of diabetes, vary by ethnic group. Of those who knew their status, 17.5% 
impacted were Black, 12.5% mixed race, and 6.0% White (Hennis et al., 2002). Adult 
Black populations are disproportionately negatively affected by diabetes than other ethnic 
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Caribbean groups. An estimated 1 in 5 Black adults are at risk for diabetes and have 
increased levels morbidity and mortality (Hennis et al., 2002). Additional risk factors 
include age, diabetes history, hypertension, high BMI and weight to height ratios, 
increased education and the level of alcohol consumption.  
Caribbean Blacks and Chronic Kidney Disease 
NCDs account for sixty-six percent (66%) of the health burden within Latin 
America and the Caribbean (LAC), this includes diabetes, CKD, cardiovascular disease, 
respiratory and digestive diseases (Anderson et al., 2009). Among the LAC, the top eight 
countries that have the highest percentages of years of life lost due to NCDs as compared 
to the percentages associated with communicable disease are Netherlands Antilles (85%), 
Cuba (73%), Uruguay (72%), Antigua (69%), Dominica (68%), Antigua and Barbuda 
(66%), Grenada (66%),  and Jamaica (66%),  (Anderson et al., 2009).Globally, as well as 
within the Caribbean, the major contributor to CKD and ESRD are chronic lifestyle-
related disease, i.e., DM and hypertension (Soyibo, Roberts, & Barton, 2011; Moeller, 
Gioberge, & Brown, 2001; Soyibo& Barton, 2007). Worldwide, treatment for ESRD 
continues to grow at 5times the population growth rate of 1.3% (Moeller, Gioberge, & 
Brown, 2002). CKD is a significant concern within the Caribbean due to many financial 
challenges. Renal replacement therapy (RRT), currently is not available in all Caribbean 
countries and cases they are available, the leading form of modality is hemodialysis 
(Soyibo et al., 2011). Within the Black American community contributing factors that 
lead to T2DM and CKD include low SES, race, poverty, obesity, inappropriate diet, low 
levels of physical activity, decreased income levels and lowered educations (Krishnan et 
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al., 2010). Soyibo et al. (2011) found however that within the Caribbean some CKD 
contributing factors include not only these factors but also lack of BP management, 
uncontrolled glucose, married with lifestyle modifications, and nutrition, if controlled, 
could reduce the increasing burden of renal failure in the region.  
It is these risks factors that contribute to the increase of CKD and diabetes 
complications within the Caribbean. Persons with CKD have not only high healthcare 
utilization rates but also mortality and morbidity rates as well (Thorp, Eastman, Smith, 
&Johnson, 2006). The prevalence and incidence of CKD through the entire Caribbean is 
currently unknown, but information is known for some more substantial islands such as 
Jamaica and St. Kitts. In a study by Ferguson et al. (2015), it was found that among 
persons attending a specialist diabetes clinic within Jamaica of the 132 participants of the 
study, 86.3% had not only diabetes but also CKD. Additionally, it was found that the 
longer a person had diabetes was associated with CKD (Ferguson et al., 2015). 
Current literature has been minimal in providing a clear and detailed look at the 
extent of CKD within the region. However minimal the information is there continuing to 
be a growing understanding and accesses to services for treatment has continued to 
improve over the years. Some countries have been more successful in providing 
necessary care and treatment within the country to their citizens, such as Grenada, 
Jamaica, Trinidad, and Barbados, but there remains continued effort to improve the 
standard of conditions and services as it relates to CNCDs within the region. 
Additionally, as prevention education increases and improves and the focus of 
encouraging persons to improve lifestyle choices, the number of CKD related deaths will 
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begin to improve. To achieve such goals, there needs to be a reduction in the incidence of 
CKD, slow ESRD progression which leads to the need for RRT and provide more 
efficient financial options for RRT (Soyibo et al., 2011). 
Microvascular Complications 
Diabetes-related complications include retinopathy, neuropathy, and nephropathy, 
which can lead to various adverse outcomes, including blindness, amputations of the 
lower limb and kidney failure (Moore, Gregory, Kumah-Crystal, & Simmons, 2009). 
Retinopathy occurs due to small vessels of the retina becoming damage due to 
uncontrolled blood sugar levels, leading to impaired vision and blindness in many cases. 
According to PAHOs Strategic Framework Visions 2020: The Right to Sight, within the 
Caribbean Region, more than 75% of persons diagnosed with DM for over 20 years will 
develop some form of diabetic related retinopathy, 10% will develop severe visual 
impairments, and about 2% will become blind. Additional contributors to retinopathy 
include high blood pressure and cholesterol. Nephropathy, when left untreated or poorly 
managed, can lead to ESRD, thus requiring either dialysis and organ transplant (Moore et 
al., 2009). The exact global impact of ESRD within the region is unknown. However, the 
WHO estimates the death burden to more than 400, 000 per year, as compared to 300,000 
in the 1995 Global Burden of Disease report (King, Roglic, Lozano, &Boshi-Pinto, 2001; 
Murray & Lopez, 2000). 
The complications related to microvascular disease, as it relates to diabetes, 
include nephropathy which leads to renal failure, retinopathy – which can lead to 
blindness, and neuropathy – which can lead to lower limb amputations (Moore et al., 
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2009). The best way to reduce a person’s risk of developing microvascular disease 
complications is to have blood sugar under control (CDC, 2014b). Nephropathy is a 
disease affecting the kidneys which can lead to CKD or ESRD thus requiring dialysis or 
organ transplant (Moor et al., 2009). As patients become hypertensive and kidney 
function decrease the risk of developing renal failure increases. 
In 2014, diabetes was described as the primary cause of 52,000 people developing 
ESRD (CDC, 2017). Unfortunately, due to health disparities, some ethnic groups are 
more impacted by this disease than other. Within the United States, non-Hispanic Blacks 
(9.0 per 1,000 persons) and Hispanics (8.4 per 1,000 persons) have a higher age-adjusted 
incidence of diabetes than their non-Hispanic White counterparts (5.7 per 1,000) (CDC, 
2017). Furthermore, persons within the Caribbean, the mortality rate due to CKD, was 
higher in 2013 for the region as compared to the world average, i.e., 18.4 and 13.3 per 
100,000 people, respectively (Health Grove, 2013). Retinopathy is a destruction of the 
retina and nerve endings impacting ones’ vision that can lead to blindness. The leading 
cause of blindness among 25 to 74-year olds in America is due to diabetic retinopathy 
(CDC, 2014b; Whitaker, 2001). According to PAHO and WHO strategic Framework 
vision 2020: The right to Sight report, diabetic eye disease is extensive in the Caribbean. 
With more than 75% of diabetic persons who have had the disease for more than 20 years 




Acute renal failure: traditionally defined as the rapid fall of the which clinically 
manifests as the abrupt and continued increase in the serum levels of urea and creatinine 
in association with disruption of salt and water homeostasis.  
Anemia: is the reduction of one or more primary red blood cell measurements, 
i.e., hemoglobin concentration, red blood cell count or hematocrit (Thomas, Kanso & 
Sedor, 2008).  
Body-Mass-Index (BMI): is determined by dividing a person’s weight (in 
kilograms) by the square of their height in meters. (WHO, 2018). 
Chronic kidney disease (CKD): abnormalities of kidney structure or function, 
present for >3 months, with implications for health (N.D., 2013). Compilation of diseases 
related to the decline of the kidney and its functions. A slow and progressive loss of 
kidney function over a period of years resulting in the need for dialysis or kidney 
transplant to maintain life (Tonelli, 2006).  
Chronic noncommunicable disease (CNCD): These are diseases of long duration 
and slow in progressions that are results of not only genetic but also physiological, 
environmental and behavioral factors (WHO, 2017). Examples of CNCDs include, but 
not limited to, cardiovascular diseases, cancers, chronic respiratory diseases, and 
diabetes. 
Diabetes mellitus (DM; i.e., Type 2 diabetes, T2DM): A condition where the cells 
no longer can efficiently use blood sugar (glucose) for energy. T2DM occurs when the 
body’s cells become insensitive to insulin and blood sugar (Oberg, Balentine, Cunha, 
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&Shiel Jr., 2017). Insulin sensitivity results in consistently chronic high blood glucose 
number above average range (ADA, 2013). 
Dialysis: the process of removing blood from an artery, purifying it, adding vital 
substances and returning it to a vein (Dialysis, n.d.) 
Dyslipidemia: is a metabolic abnormality leading to a persistent increase in the 
plasmatic concentration of cholesterol and triglycerides (Moor et al., 2017). 
End stage renal disease ESRD: Is the last stage of chronic kidney disease (stage 
5), this results in the need for either dialysis or a kidney transplant (Thomas, Kanso, 
&Sedor, 2008).  
Hyperglycemia: Another name for high blood sugar, is clinically defined as blood 
glucose levels greater than 7.0 mmol/L (126 mg/dl) when fasting or a blood glucose level 
higher than 11.0 mmol/L (200 mg/dl) 2 hours after meals (Diabetes CO.UK, 2018). 
Hypertension: When the systolic blood pressure readings are higher than 140, and 
diastolic blood pressure is higher than 90 due to thickening of arteries (CDC, 2014). 
Hypertension is a long-term medical condition in which the blood pressure ithe arteries 
remains elevated for an extended amount of time. 
Incidence: measures the rate of occurrence of a new case of condition or disease 
(Roe & Doll, 2000) 
Insulin: Wilcox (2005) defines insulin as, “a peptide hormone secreted by the β 
cells of the pancreatic islets of Langerhans and maintains normal blood glucose levels by 
facilitating cellular glucose uptake, regulating carbohydrate, lipid and protein metabolism 
and promoting cell division and growth through its mitogenic effects.” 
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Lacunar infarcts: small infarcts (2-20 mm in diameter) located in deep cerebral 
white matter, basal ganglia or pons; thought to a result of occlusion of a single small 
perforating artery supplying sub cortical areas of the brain (Wardlaw, 2004).  
Macrovascular disease (MVD): the disease of the large blood vessels, this 
includes the coronary arteries, aorta, and large arteries of the brain and limbs 
(Macrovascular disease, n.d.). 
Microvascular disease (MVD): is the presence of retinopathy and lower extremity 
numbness and or amputation. Diseases are resulting from poor control of blood sugar 
(hyperglycemia) resulting in injury to small blood vessels which can lead to such 
conditions as retinopathy, neuropathy, and nephropathy (CDC, 2014a).  
Mineral bone disease: commonly occurring in persons with CKD, occurs when 
damaged kidneys and abnormal hormone levels cause calcium and phosphorus levels to 
become out of balanced in the blood (n.d., 2015) 
Nephropathy: is defined by macroalbuminuria or a urinary albumin excretion of 
more than 300 mg in 24 hr. collection. It is often characterized by a progressive increase 
in protein urea and decline in GFR, hypertension and a high risk of cardiovascular 
morbidity and mortality (Butt, Hall, &Nurko, 2010). 
Obesity: Obesity is the excessive or abnormal build up of fat that presents a risk 
to a person’s health (WHO, 2018). A person with a body-mass-index (BMI) of greater 
than 30 is considered obese. 
Prevalence: The overall number of persons living with a disease. (CDC, 2014a). 
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Risk factors: Factors that create or contribute to the development of a disease or 
leads to the increased decline of the disease condition (CDC, 2014a). 
Assumptions 
The following assumptions were made in this study. 
 Medical files documented microvascular disease accurately. 
 CKD severity level is clearly identified in all microvascular disease cases. 
 Data were entered in efficient and effective manner with minimal errors. 
 No bias was introduced in the study due to the random occurrence of missing 
data.  
 The expected dependent and independent variables were contained in the 
secondary data set identified for this study. 
 The manners of the data voluntarily released the data set for this analysis upon 
request. 
 Dataset had enough cases and variable for unbiased study of the variables of 
interest 
Considering these assumptions enhanced the validity of the study. 
Limitations 
The following limitations of this study are hereby acknowledged: 
 This study was a secondary data analysis, thus some variables that may have 
added value to the study were not be in the dataset. 
 Missing data may have affected the inferences drawn from this study and the 
researcher could not modify the dataset to ensure no missing data 
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 This dataset was collected more than 2years prior to the study and the current 
reality on ground in Grenada may have changed markedly. 
 The quality of the data set is dependent on the researchers and field workers 
who collected the primary data, the statisticians and data clerks who inputted 
the data, and the capacity of the staff who oversee the data set at the records 
department in Grenada. 
 The quality of the data set may have been affected by the level of data 
collection standards and regulations set by the Ministry of Health in Grenada 
the various manipulations of the data set over the past 2 years. 
Scope and Delimitations 
This study is based on 2016 Grenada General Hospital medical records of CKD 
patients and the socioecological factors that influence associations of MVD among CKD 
patients with T2DM in Grenada. There was no contact with study participants or primary 
data collected. There was a difference in time from when the information was collected 
and when the secondary data analysis was taken place.  
The delimitations of this study include: 
 This study was delimited to quantitative cross-sectional descriptive study. 
 It was use entirely secondary data no primary data will be gathered.  
 The study was delimited to the variables present in the dataset selected for this 
study. 




 The study was delimited by time of data collection during patient clinical 
visits to the general hospital from 01/01/2016 to 12/31/2017. 
Significance of the Study and Potential for Social Change 
The purpose of this study was to determine if there is an association between 
microvascular disease and CKD severity in persons with diabetes evaluate the prevalence 
of MVD and how it relates to CKD severity in individuals with diabetes, in Grenada, 
West Indies. This project will be unique in that it will be the first of its kind within the 
region to look at diabetes from a pathophysiological level as well as its potential 
relationship to CKD about such matters of diabetic neuropathy and diabetic lower-
extremity amputations. The results of this study will provide much-needed insight into 
the impact of MVD not only among the CKD and diabetic community but also on the 
healthcare system overall.  
This study will provide the potential for valuable insights into the overall 
knowledge of microvascular disease as it relates to CKD and T2DM, especially in this 
population. This study aims to close the gap in the literature about the understanding of 
the potential link between microvascular disease and CKD among Grenadian. Within the 
last 5years, that has only a few studies on CKD and diabetes within the Caribbean, 
including St. Lucia. This study adds to these findings and could provide the basis for 
innovations, and strategic planning for interventions for the improved management of 
CKD, and prevention initiatives. Several studies have shown the prevalence of CKD and 
diabetes within the Caribbean and Grenada. However, no quantitative study was found 
that explores the potential relationship between MVD and these diseases within Grenada. 
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It also has the potential to improve how medical reports are documented as it relates to 
documentation of critical medical conditions.  
This study has three potential implications for social change. (a) knowledge of 
CKD complications as it relates to diabetic patients. This finding has the potential to 
identify the extent of this health issue within the country. Currently, within the 
Caribbean, there is much knowledge about diabetes and growing community knowledge 
about kidney disease, but the extent to which CKD impacts communities is still unknown 
(b). Determine the relationship between MVD and CKD in persons with diabetes. These 
findings have the potential for the development of policy changes in how reporting is 
done as it relates to microvascular disease and CKD in diabetic patients. (c) Lifestyle 
modification recommendations are another potential social change that can set the 
groundwork for reducing the impact of these diseases on the country. No research is 
currently available as it relates to the overall cost of MVD within Grenada. However, it 
serves as a potential topic of study through grant funding. 
Summary and Conclusions 
This section I elaborately described the problems related to exploring the link 
between MVD and CKD severity among T2DM patients and provided some background 
into the topic of MVD and its various contributing factors. Additionally, the purpose of 
the study, the nature of the study, the research questions and hypothesis, a detailed 
literature review with emphasis on limitations, delimitations and assumptions were given. 
The section ended with a description of the social change impact of the study. Section 2 
focused on the methodology to be used for this investigation. This section will include a 
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description of the population to be studied, the dataset used, an elaboration of the data 




Section 2: Research Design and Data Collection 
Introduction 
The purpose of this quantitative, cross-sectional study was to determine if there is 
an association between MVD and CKD severity in persons with diabetes and to evaluate 
the prevalence of MVD. In the previous section, I provided background on the topic, 
described the problems related to exploring the link between MVD and CKD severity 
among T2DM patients, the research questions, a detailed literature review, and the study 
implications to social change. In this section, the study design, methodology, the nature 
of the study, the operational variables, ethical considerations, and data management 
processes are described. 
Research Design and Rationale 
In this study, after reviewing various study designs by Creswell (2009), I decided 
to use the descriptive, retrospective, cross-sectional study design. The data were collected 
from the medical records department from 2013 to 2017. Using secondary data not only 
saved time but was also more cost effective than doing primary data collection. Although, 
many datasets require an access fee, the data were already collected which reduced the 
time of collecting data as compared to primary data collection and analysis, reducing 
duplication (Cheng & Phillips, 2014). Additionally, using secondary data minimizes 
potential ethical issues that are more commonly associated with primary data collection, 




In this subsection, I provide a description of how the study was carried out. The 
subsection includes a discussion of the study area/population, secondary data 
management processes, sampling techniques, and sample size. 
Study Area 
Grenada is a tri-island country (i.e., Grenada, Carriacou, and Petite Martinique) 
made up of seven parishes and has population of over 100,000 and a median age of 33.3 
years old (The World Factbook, 2020). There is one government parliament with the 
parishes being divided into 15 constituencies that are governed by elected party officials 
(The World Factbook, 2020). For this study, the data were obtained from the hospital, 
which serves persons from each constituency. I obtained sample data from the medical 
record department to capture all persons who may qualify for the study who receive CKD 
and diabetes treatment.  
Secondary Data Set Management 
I used the hospital medical records as the secondary data set in this study. 
Approval for the study was sought from the ministry of health who are the owners and 
holders of the medical records. Their approval allowed me not only access to the data for 
study but also potentially the ability to publish findings at the end of the study (see 
Appendix A). I received official approvals from the Walden University Institutional 
Review Board (IRB), and the Government of Grenada. Once this was confirmed, a 
descriptive analysis was run to better confirm its accuracy and identify any missing data 
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Figure 2. Data management processes. 
Sampling and Sampling Procedures 
The country of Grenada is a moderately sized country population with many 
persons using the general hospital. This allowed for ease of conducting a randomized 
sample of the study participants for the purpose of a statistically appropriate 
 
Retrieval and review of data set 
 
Request for data set 
 
Identification of Data Source 
35 
 
representation of the population. In this study, I employed a simple random sampling 
technique. The simple randomization of the cases was appropriate in addressing the 
research questions and subsequent variables. The benefit of using this sampling technique 
is that it provides an unbiased representation of the population group studied. 
Inclusion and Exclusion Criteria 
In this study, the participants included individuals of all sexes above the age of 16 
years old, whether visitors, permanent residents, or citizens within the tri-island country. 
This decision was made to ensure that there was a large enough sample size and to reduce 
any potential selection bias to the study. Persons that do not have CKD and/or T2DM 
were excluded from the study. These exclusion criteria were included because the 
purpose of the study was to determine the association between MVD and CKD in persons 
with diabetes in Grenada.  
Data Collection Tools 
I used medical records from the hospital for this study. The dataset holders were 
asked for access and permission to review the medical record archives. This application 
for access and permission was requested to the appropriate persons who had the 
authorization to release the medical records. The data set holders approved my request. 
I gathered data on the independent variables of interest, such as age, sex, A1C 
level, alcohol, and BP at time of study, from the medical chart and BMI was re-coded to 
establish categories for the use of binomial logistic regression analysis. The dependent 
variable was CKD Stages3 through 5, so I could establish the severity of the disease in 
comparison to diabetes and the potential association to MVD. 
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Quality Assurance and Control 
I ensured the quality of the study using the data set analysis tool, Statistical 
Package for the Social Sciences (SPSS), Version 25 (see IBM Corp, 2012). Outliers, 
missing data, and errors in the consistency of the data set were established through 
preliminary descriptive analyses. I carried out continued reviews of the data set to ensure 
the variables and data collected was within the scope of the study parameters. 
Procedures for Gaining Access to the Data Set 
I contacted the medical records department at the hospital about the procedures 
for obtaining access to medical records for research on topic. Next, I spoke to the senior 
medical officer and the general hospital nephrologist about my interest and intent to do 
this study. I was instructed on the best way to gain access to data on the variables of 
interest in the study would be to evaluate the files of those who had kidney disease and 
then identify diabetes and then look for any associations. Before using the secondary 
data, particularly medical records, from another country, I obtained IRB approval from 
Walden University (IRB Approval # 10-12-18-0599663) as well as study approval from 
the Ministry of Health in Grenada. I waited for approval from the dataset holders, which 
came a few days to weeks later with specific instructions on where to access the data, 
what to do with it, and what to do with the report/publications that may result from the 
analysis. 
With the permission in hand, I began accessing the medical records; saved data 
set variables to my password-protected, portable hard drive; and began analysis. First, I 
reviewed both the data dictionary and the dataset to ensure that all the required variables 
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for the study were in the set. Once this was confirmed, I ran a univariate, descriptive 
analysis to have a better understanding of the data (i.e., the accuracy, skewness, kurtosis, 
missing data, and even outliners see Green &Salkind, 2014). 
Sample Size 
In this study, I used a sample size calculator to determine the appropriate sample 
size for the population. The sample size was determined by setting the confidence level at 
95%, a confidence interval of five, and using a population size of 100,000. The resulting 
sample size recommended for the study was 383 medical records. The numbers of males 
to females within the study from the sample was determined upon reviewing the data. 
The total sample size after cleaning the data was 770 cases. 
Justification for the Effect Size, Alpha Level, and Power Level Chosen 
To improve the validity of the study, I selected an effect size. An alpha level of 
0.5 was used to reduce Type 1 error and a power level of 80% was used to reduce Type 2 
error. The choice of these figures was made for better external validity and improved 
outcomes concerning generalization of the study findings.  
Instrumentation and Operationalization of Constructs 
In this study, I used the medical records of treatment, diagnosis, and 
demographical information from the hospital as a secondary data set. In the following 
subsections, the operationalization, target population, and data technique used for this 




MVD association was the dependent variable in this study. The key independent 
variables in this study were the individual and socioeconomic factors of the participants 
in the hospital medical records from the years of 2013 to 2017. These included age, 
gender, BMI, alcohol use, smoking, and A1C. I dichotomized the variables for logistic 
regression analysis (e.g.,  persons age was reclassified into categories of less than 35 
years old and above 35 years old, and marital status was classified into married and 
single, with single being further broken down to include divorced, widowed, or 
separated).  
Target Population 
In this study, the target population was persons who were diagnosed as having 
CKD and diabetes during 2017. Any persons in the medical records that were over the 
age of 16 years old and met the preceding criteria were considered for the study because 
the legal definition of an adult in Grenada is those aged16 or older. Any person that did 
not fit these basic criteria was not included in the study, including children under the age 
of 16 years old.  
Data Collection Technique 
The data set was collected over a period of 12 months by hospital staff, especially 
the nephrologists from 2013 to 2017. However, the field work was estimated to occur 
from April 2018 – May 2018.I gathered the data for this study through the reviewing of 




Research Questions and Hypotheses 
RQ1: Is there an association between MVD and CKD severity among diabetes 
patients with or without hypertension, when controlling for age, AIC, BMI, 
gender, alcohol use, and smoking? 
H01: There is no statistically significant association between MVD and 
CKD severity among diabetes patients in Grenada with or without 
hypertension when controlling for age, AIC, BMI, gender, alcohol use, 
and cigarette smoking. 
HA1: There is a statistically significant association between MVD and 
CKD severity among diabetes patients in Grenada with or without 
hypertension when controlling for age, A1C, BMI, gender, alcohol use, 
and cigarette smoking. 
RQ2: What is the significance between the prevalence of MVD and CKD severity 
among patients in Grenada with diabetes with or without hypertension when 
controlling for age, A1C, BMI, gender, alcohol use, and smoking?  
H02: There is no significance between prevalence of MVD and CKD 
severity among patients in Grenada with diabetes with or without 
hypertension when controlling for age, A1C, BMI, gender, alcohol use, 
and smoking.  
HA2: The prevalence of MVD is ≥ 50%of CKD patients in Grenada with 
diabetes with or without hypertension when controlling for age, BMI, 
A1C, gender, alcohol use, and smoking. 
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Data Analysis Plan 
The analysis was in line with Figure 3. 
 
Figure 3. Data analysis process. 
SPSS version25was used to analyze the data (IBM Corp, 2012). The data set was 
validated using built in validation functions in SPSS. Then a simple descriptive analysis 
was conducted. Identified variables were categorized and manipulated in accordance to 
the research questions for effective data analysis. Charts, tables and graphs will be 
created for visual description of the dataset. The first research question of if there is an 
association between MVD and CKD severity among diabetes patients with or without 
hypertension, when controlling for age, height, AIC, BMI, gender, smoking, and weight, 
the statistical tests used to test this hypothesis will be the chi-square test and the binomial 


















logistic regression due to the dependent variable being nominal and having more than 
two categories. 
The second research question, what is the significance between the prevalence of 
MVD and CKD among patients with diabetes with or without hypertension when 
controlling for age, A1C, BMI, gender, alcohol, and smoking in Grenada, according to an 
organizational variables arising from the foundation of the SEM was statistically 
evaluated by using the binomial logistic regression due to the dependent variable being 
nominal and having more than two categories.  
Threats to Validity 
Since it is unclear if the medical records have been validated in the past, there is a 
potential of several threats to the studies validity. Being a secondary data analysis, there 
may have limitations to construct validity, limited number of variables available for 
analysis with absence of some essential variables, inherent bias, missing data and 
unaccounted errors in data collection. In addition, as this data were collected from 2013 
to 2017, there could be significant changes to data storage and access to data archived 
medical data in Grenada. To minimize these threats, the data were validated using the 
SPSS preloaded rules.  
Limited work hours, lack of clearance to enter some data on a regular basis, and 
lack of access to power outlet in available data area may affect coverage and limited 
internal validity of the project. Also, there may have inconsistent documentation of 




This study involved indirect research with human subjects as it entailed analysis 
of secondary data looking at key variables collected in the 2013 to 2017 medical records. 
The proposal has been approved by the primary data collector and data were collected 
(The DHS Program, n.d.), because ethical approvals have been approved by the Walden 
University IRB prior to proceeding to data retrieval, analysis and report development. 
Relevant additional approvals for the form the data holders – Grenada Ministry of Health 
Research Committee was obtained. These approvals enabled me to enter the data, analyze 
and develop result report. The approvals gave me the permission to publish the findings 
of the study in peer reviewed journals. As the dataset still belonged to the Government of 
Grenada, all saved data sets were deleted from my portable hard drive after analysis and 
report development. The product of this secondary data analysis was shared with the 
Grenada Ministry of Health – if they request for it. Individual identifying information 
was removed, and data anonymized to protect the participants before the analysis.  
Dataset Treatment Post Analysis 
Data set was deleted from the system upon completion of analysis and study. 
Summary 
In Section 2 of this inquiry, I elaborated on the research design (cross-sectional 
quantitative approach of inquiry), rationale and methodology of the study. In describing 
the methodology, the study population (Grenada), study area using the 2013 - 2017 
medical records from the hospital, national population census, secondary data set 
management technique, sampling and sampling procedure, and instrumentation and 
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operationalization of constructs were described. In describing the instrumentation and 
operationalization of constructs, the section operationalized the variables by explaining 
the dependent and independent variables and their means of measurement, data collection 
and management techniques and data analysis plan. In addition, the section also discussed 
threats to validity and ethical considerations and procedures. In Section 3, we 




Section 3: Presentation of Results and Findings 
Introduction 
The purpose for this quantitative, cross-sectional study was to determine if there 
is an association between MVD and CKD severity in persons with diabetes in Grenada 
among persons who visited the hospital between 2013 and 2017as well as to evaluate the 
prevalence of MVD. The research questions and hypotheses that guided this study were: 
RQ1: Is there an association between MVD and CKD severity among diabetes 
patients with or without hypertension, when controlling for age, AIC, BMI, 
gender, alcohol use, and smoking? 
H01: There is no statistically significant association between MVD and 
CKD severity among diabetes patients in Grenada with or without 
hypertension when controlling for age, AIC, BMI, gender, alcohol use, 
and smoking. 
HA1: There is a statistically significant association between MVD and 
CKD severity among diabetes patients in Grenada with or without 
hypertension when controlling for ageA1C, BMI, gender, alcohol use, and 
smoking. 
RQ2: What is the significance between the prevalence of MVD and CKD severity 
among patients in Grenada with diabetes with or without hypertension when 
controlling for age, A1C, BMI, gender, alcohol use, and cigarette smoking? 
H02: There is no significance between prevalence of MVD and CKD 
severity among patients in Grenada with diabetes with or without 
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hypertension when controlling for age, A1C, BMI, gender, alcohol use, 
and cigarette smoking.  
HA2: The prevalence of MVD is ≥ 50%and CKD patients in Grenada with 
diabetes with or without hypertension when controlling for age, BMI, 
A1C, gender, alcohol use, and cigarette smoking. 
In this section, I present the data collection, the results, and a summary. I analyzed 
the hospital medical records of patients with diabetes and CKD for the for mentioned 
year range using SPSS Version 25. The data were validated using SPSS validation 
functions. Descriptive analyses of both the recoded, when necessary, and coded variables 
were conducted to align with the research questions. Data were then cleaned to spot and 
rectify data errors, mitigating its potential negative impact on study results. Next, I 
reviewed the analyzed data to ensure validity and conducted further analytical tests using 
SPSS.  
Data Collection of Secondary Data Set 
For this study, I used the medical records from a hospital in Grenada, West Indies. 
Patient medical files were obtained through the medical records department of the 
hospital, and medical records department staff was guided by the proposal for data 
collection from 2013 to 2017. The General Hospital is the main hospital for the tri-islands 
of Grenada, Carriacou, and Petite Martinique. Patient files used for analysis were 
gathered by the medical records department of the hospital based on the research criteria 
of the person’s initial hospital interactions (i.e., diabetes, CKD, and hypertension),which 
was approved by IRB committee, and were presented to me as they were available. Due 
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to limited staffing, files only became available when the staffing was available to gather 
the data between their other duties to the hospital. Patient files contained a minimum 
primary diagnosis of diabetes, and many contained not only secondary diagnoses but also 
various procedural codes.  
The use of medical records is essential to the determination of the effectiveness of 
not only the healthcare system but also for the evaluation of patient care. Though there 
are other medical facilities on the islands, all major medical procedures and specialists 
are located at the hospital. The 2013 to 2017 medical records contain data that represents 
the population of Grenada, Carriacou, and Petite Martinique. It is through evaluation of 
these records that I determined if the study null hypotheses could be accepted or rejected. 
Limitations 
There were a few discrepancies related to the secondary data collection for 
analysis. I originally proposed to use only data from 2016; however, due to the small 
sample size, this was updated to use all patient files from 2013 to 2017, thus making the 
study a retrospective analysis. The change in data set study range resulted in a longer 
time for data collection timeframe than intended. Additionally, many basic fields were 
missing in the intake portion of the patient’s files. For example, height, weight and BP 
were either incorrectly noted (e.g., obese for weight, A1C, or instead of a number the 
words HI for BP) or not noted at all. This caused difficulty in determining BMI for many 
for the patient files, and therefore, the data were not controlled for this variable along 
with weight, A1C, height, and BMI.  
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The data screened for patients aged 16–100 years old with a diagnosis of diabetes 
resulted in 998 records. However, due to many files missing data for the specific study 
period or having no laboratory report or medical notation of laboratory procedures done, 
the final sample included 770medical records. Female participants made up the largest 
demographic group (57.9%). Most participants (58.8%) were between, equal, to or over 
the age of 60 years old, with many participants (76.7%) being diagnosed with having 
hypertension and 35.6% of persons found to have Stage 2 CKD. Table 1 shows the 
frequency of participants by population characteristics. Additionally, most of the 
participants were reported as not smoking (92.1%) or drinking (77%), with many 
participants reporting their frequency of drinking or smoking as never (78.3%, 89.7%, 
respectively). As it relates to CKD severity and being categorized as either less severe 
(i.e., CKD Stage 1 or 2) or severe (i.e., CKD Stage 3A, 3B, 4, or 5) determined by eGFR, 
most cases was defined as less severe CKD (57.6%). See Tables 1 and 2. 
Table 1 
 
Frequency Distribution for Study Population Characteristics 







































































Frequency Distribution for Research Sample 
























Smoke Yes 60 7.9 
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No 695 92.1 



















In order to answerRQ1, I first conducted descriptive statistics for the variables of 
(a) age, (b) A1C, (c) BMI, (d) gender, (e) smoking, (f) hypertension, and (g) CKD 
severity. Age, BMI, and A1C were continuous variables; however, due to many variable 
points missing for height, weight, BMI, and A1C, they were not included in the 
analysis(see Table 3). The ordinal variables of gender, smoking, alcohol use, 
hypertension, and CKD severity, are represented in Table 3. A chi-square test was 
conducted to determine association to address RQ1 of this study. This test was used as 
the primary statistical analysis for evaluating whether there was an association between 
CKD and its various potential contributing health behavior factors. Finally, a binomial 
logistic regression was conducted to determine if MVD was predicted by the independent 
variables of age group, gender, smoking, cholesterol, ACR severity, hypertension, and 
MVD and the dependent variable of CKD. 
Table 3 
 
Variables Removed from the Analysis 
Category # of Possible Cases # of Missing Data 
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BMI 770 732 
Height 770 706 
Weight 770 676 
A1C 770 545 
Table 4 
 
Binary Logistic Regression Analysis Predicting Likelihood of Chronic Kidney Disease Severity 
Association without Drinking with p value, OR, and 95% CI 
Variables B p value OPR 95%CI 
 
Lower                 Upper 
Gender (ref = 
female) 
0.207 0.480 1.230 0.692 2.184 
Age 0.304 0.009 1.355 1.080 1.702 
Smoke  
(ref = no) 
-0.868 0.104 0.420 0.147 1.196 
Cholesterol 
(ref = high) 
-0.009 0.976 0.991 0.535 1.836 
ACR severity 0.223 0.632 1.250 0.502 3.114 
          Hypertension 
(ref = yes) 
-0.571 0.130 0.565 0.270 1.182 
MVD 0.019 0.968 1.020 0.398 2.614 
Constant -3.279 0.026    
 
Using the sample size of N= 761, I conducted a chi-square test for association to 
evaluate whether a person’s gender is associated with CKD. The two variables were the 
gender of the participants with two levels (i.e., male and female) and the diagnosis of 
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CKD with two levels (i.e., less severe and severe). The results in Table 5showed no 
statistically significant association between a person’s gender and CKD diagnosis, X2 (1) 
= 0.607, p = 0.436, Cramer’s V = 0.028. Therefore, I failed to reject the null hypothesis 
that there was no association between the gender and CKD. Cramer’s V correlation also 
provides the strength of the relationship. A value of 0 indicates no association or 
difference, and a value of 1.0 indicates a very strong or perfect association. Cramer’s V 
correlation showed a very weak or no association between the variables. 
Table 5 
 
Chi-Square Results for Gender and Chronic Kidney Disease Severity 
Variables Value df p value 
Person chi-
square (X2 ) 
0.607 1 0.436 
Likelihood 
ratio 
0.608 1 0.436 
Cramer’s V 0.028  0.436 
N of valid 
cases 
761   
 
The cross-tabulation chi-square test of gender as it relates to CKD severity in 
Table 6shows that 43.4% (190 out of 438) of male participants was found to have a less 
severe case diagnosis of CKD severity and 40.6% (131 out of 323) was found to have a 
severe case diagnosis of CKD severity, while 56.6% (248 out of 438) of female 
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participants was found to have less severe case diagnosis of CKD severity and 59.4% 
(192 out of 323) had a severe case diagnosis of CKD severity. The results from the chi-
square tests for association, as shown in Table 5 & 6,failed to reject the null hypothesis 
that there was no statistically significant association between the patients’ gender and 





Chi-Square Results Crosstabulation for the Development of Chronic Kidney Disease Severity and 
Gender 
   Gender 
Male                      Female 
Total 
CKD Less severe Count 190 248 438 
  Expected 
Count 
184.8 253.2 438.0 
  % within CKD 43.4% 56.6% 100.0% 
 Severe Count 131 192 323 
  Expected 
Count 
136.2 186.8 323.0 
  % within CKD 40.6% 59.4% 100.0% 
Total  Count 321 440 761 
  Expected 
Count 
321.0 440.0 761.0 
  % within CKD 42.2% 57.8% 100.0% 
Utilizing the sample size valid cases N= 753, a Chi-square test for association was 
conducted to assess the association between hypertension and CKD severity. The two 
variables were hypertension with two levels (Yes and No) and the contraction of CKD 
with two levels (less severe and severe). Table 8(chi-square cross-tabulation table) shows 
that 82.2% of the participants diagnosed with hypertension was shown to have severe 
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CKD levels, while 17.8% of the patients without hypertension tested was found to have 
had severe CKD levels. Seventy-three percent of patients that did have hypertension had 
less severe CKD, while 27% without hypertension had less severe CKD. The result in 
Table 7 reveals a statistically significant association between the presence of 
hypertension and CKD severity, X2(1) = 9.61, p<0.05, Cramer’s V = 0.11. As a result, the 
null hypothesis should be rejected that there was no statistically significant association 
between hypertension and CKD severity. The observed difference is statistically 
significant, and therefore is proof to reject the null hypothesis. Cramer’s V correlation in 
Table 7also provides the strength of the relationship. Cramer’s V correlation shows a 
small effect between the variables. The result as shown in Table 7validates the alternative 
hypothesis that there was an association between hypertension and CKD severity. 
Table 7 
 
Chi-Square Results for Hypertension and Chronic Kidney Disease Severity 
Variables Value df p value 
Person chi-
square (X2 ) 
9.608a 1 0.002 
Likelihood 
ratio 
9.809 1 0.002 
Cramer’s V 0.113  0.002 
N of valid 
cases 






Chi-Square Results Crosstabulation for the Development of Chronic Kidney Disease Severity and 
Hypertension 
 
   Hypertension 
 




CKD Less severe Count 314 119 433 
  Expected 
Count 
331.8 101.2 433.0 
  % within CKD 72.5% 27.5% 100.0% 
 Severe Count 263 57 320 
  Expected 
Count 
245.2 74.8 320.0 
  % within CKD 82.2% 17.8% 100.0% 
Total  Count 577 176 753 
  Expected 
Count 
577.0 176.0 753.0 
  % within CKD 76.6% 23.4% 100.0% 
 
Using the sample size of N= 723, a chi-square test for association was conducted 
to evaluate whether ACR severity is associated with CKD. The three variables were the 
ACR of the participants with three levels (normal to mildly increase, moderately severe, 
and severely increased) and the diagnosis of CKD with two levels (less severe and 
severe). The result in Table 8 shows no statistically significant association between ACR 
severity and CKD diagnosis, X2(2) = 2.194, p = .334, Cramer’s V = 0.055. Therefore, the 
null hypothesis could not be rejected that there was no association between the ACR 






Chi-Square Results for ACR Severity and Chronic Kidney Disease Severity 
Variables Values Df p value 
Person chi-square (X2) 2.194 2 0.334 
Likelihood ratio 2.166 1 0.339 
Cramer’s V 0.055  0.334 
Number of valid cases 723   
 The cross-tabulation chi-square of gender as it relates to CKD severity in Table 
10 show that 3.1% (13 out of 420) of persons with normal to mildly increased ACR 
levels was found to have less severe case diagnosis of CKD; 92.9% (390 out of 420) of 
persons with moderately severe ACR levels was found to have less severe case diagnosis 
of CKD; and 4.0% (17 out of 420) of persons with severe ACR levels was found to have 
less severe case diagnosis of CKD. In comparison, the same table showed that 4.6% (14 
out of 303) of persons with normal to mildly increased ACR levels was found to have 
severe case diagnosis of CKD; 89.8% (272 out of 303) of persons with moderately severe 
ACR levels was found to have severe case diagnosis of CKD; and 5.6% (17 out of 303) 
of persons with severe ACR levels was found to have severe case diagnosis of CKD. The 
results from the chi-square test for association as shown in Table 8 and9 sustain the null 
hypothesis that is no statistically significant association between ACR severity and CKD 





Chi-Square Results Crosstabulation for Chronic Kidney Disease Severity and ACR Severity 
   ACR Severity  








CKD Less severe Count 13 390 17 420 
  Expected 
Count 
15.7 384.6 19.8 420.0 
  % within 
CKD 
3.1% 92.9% 4.0% 100.0% 
 Severe Count 14 272 17 303 
  Expected 
Count 
11.3 277.4 14.2 303.0 
  % within 
CKD 
4.6% 89.8% 5.6% 100.0% 
Total  Count 27 662 34 723 
  Expected 
Count 
27.0 662.0 34.0 723.0 
  % within 
CKD 
3.7% 91.6% 4.7% 100.0% 
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With the sample size valid cases N= 255, a Chi-square test for association was 
conducted to assess the association between cholesterol and CKD severity. The two 
variables were cholesterol with two levels (normal and high) and the contraction of CKD 
with two levels (less severe and severe). Table 12(chi-square cross-tabulation table) 
shows that 72.7% of the participants with normal cholesterol levels were shown to have 
severe CKD levels, while 27.3% of the patients with high cholesterol tested were found 
to have severe CKD levels. Seventy-two percent of patients that had normal cholesterol 
had less severe CKD, while 28% with high cholesterol had less severe CKD. The result 
in Table 11 revealed no statistically significant association between the cholesterol and 
CKD severity, X2(1) = 0.034, p = 0.847, Cramer’s V = 0.012. As a result, the null 
hypothesis should be accepted that there is no statistically significant association between 
cholesterol and CKD severity. The observed difference is not statistically significant, and 
therefore was proof to accept the null hypothesis. Cramer’s V correlation in Table 10 also 
provides the strength of the relationship. Cramer’s V correlation shows a small to no 
effect between the variables. The result as shown in Table 11validates the null hypothesis 





Chi-Square Results for Cholesterol and Chronic Kidney Disease Severity 
Variables Value df p value 
Person’s chi-square (X2) 0.037 1 0.847 
Likelihood ratio 0.003 1 0.847 
Cramer’s ratio 0.012  0.847 




Chi-Square Crosstabulation for Chronic Kidney Disease Severity and Cholesterol 
   Cholesterol 
Normal          High 
 
   Total 
CKD Less severe Count 96 38 134 
  Expected 
Count 
96.7 37.3 134.0 
  % within CKD 71.6% 28.4% 100.0% 
 Severe Count 88 33 121 
  Expected 
Count 
87.3 33.7 121.0 
  % within CKD 72.7% 27.3% 100.0% 
Total  Count 184 71 255 
  Expected 
Count 
184.0 71.0 255.0 
  % within CKD 72.2% 27.8% 100.0% 
 
Observing the sample size of valid cases N= 761, a Chi-square test for association 
was conducted to assess the association between MVD and CKD. The two variables were 
MVD with two levels (yes and no) and the development of CKD with two levels (less 
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severe and severe). Table 14(chi-square cross-tabulation table) shows that 12.4% of the 
participants diagnosed with MVD was shown to have severe CKD levels, while 87.6% of 
the patients without MVD tested was found to have severe CKD levels. Fifteen percent of 
patients that did have MVD had less severe CKD, while 85% without MVD had less 
severe CKD. The result in Table 12 revealed no statistically significance association 
between the presence of MVD and CKD severity, X2(1) = 0.782,p = 0.376, Cramer’s V = 
0.032. As a result, the null hypothesis should be accepted that there was no statistically 
significant association between MVD and CKD severity. The observed difference is not 
statistically significant, and therefore is proof to accept the null hypothesis. Cramer’s V 
correlation in Table 13also provides the strength of the relationship. Cramer’s V 
correlation shows a small effect between the variables. The result as shown in Table 12 




Chi-Square Results Microvascular Disease and Chronic Kidney Disease Severity 
Variables Value df p value 
Person chi-square (X2 ) 0.782a 1 0.376 
Likelihood ratio 0.788 1 0.375 
Cramer’s V 0.032  0.376 






Chi-Square Cross-Tabulation for Chronic Kidney Disease Severity and Microvascular Disease 
   MVD _Recode  
   Yes No Total 
CKD Less severe Count 64 374 438 
  Expected 
Count 
59.9 378.1 438.0 
  % within CKD 14.6% 85.4% 100.0% 
 Severe Count 40 283 323 
  Expected 
Count 
44.1 278.9 323.0 
  % within CKD 12.4% 87.6% 100.0% 
Total  Count 104 657 761 
  Expected 
Count 
104.0 657.0 761.0 
  % within CKD 13.7% 86.3% 100.0% 
 
The result from the logistic regression analysis in Table 15shows that age group 
and drinking does significantly predict the odds of CKD severity among the participants 
while controlling for gender, and smoking(OR = 1.320, 95% CI [1.191-1.463], p< 0.05; 
OR = 1.801, 95% CI [1.212-2.676], p<0.05, respectively). The result showed that the 
difference in age and drinking was associated with the development of CKD. As a result, 
I accepted the alternative hypothesis of statistically significant difference in the odds of 
developing CKD between age groups, as well as drinking or non-drinking, and reject the 
null hypothesis of no significant odds of CKD contraction between age groups, plus 
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drinking or non-drinking, after adjusting for gender, and smoking. In contrast, Table 
15shows that gender and smoking status did not significantly predict the odds of 
developing CKD among the participants while controlling for age group, and drinking 
(OR = 1.012, 95% CI [0.737-1.390],p =  0.939; OR = 1.759, 95% CI [0.923-3.353], p 
=0.086, respectively). Therefore, the result shows that the differences in gender and 
smoking or non smoking were not associated with the development of CKD. As a result, 
I rejected the alternative hypothesis of statistically significant difference in the odds of 
developing CKD between male and female and smoking and non smoking, and accept the 
null hypothesis of no significant odds of CKD contraction between male and female and 
smoking and non smoking after adjusting for age, and drinking. 
Table 15 
 
Binary Logistics Regression Analysis Predicting Likelihood of Chronic Kidney Disease Severity 
Association with p value, OR, and 95% CI 
Variables B p value OR 95% CI 
    Lower Upper 
Gender (ref = male) 0.012 0.939 1.012 0.737 1.390 
Age 0.278 0.000 1.320 1.191 1.463 
Smoke  
(ref = no) 
0.565 0.086 1.759 0.923 3.353 
Drink status 
(ref =no) 
0.589 0.004 1.801 1.212 2.676 
Constant -3.802 0.000    
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 The result from the logistic regression analysis in Table 16 shows that cholesterol, 
ACR severity and MVD does not significantly predict the odds of developing CKD 
among the participants while controlling for age, gender, smoking, and drinking (OR = 
0.904, 95% CI [0.509-1.606], p = 0.73; OR = 1.296, 95% CI [0.532-3.157], p = 0.57; OR 
= 1.043, 95% CI [0.417-2.607], p = 0.93 respectively). The result shows that the 
difference in cholesterol, ACR severity and MVD are not associated with the 
development of CKD. As a result, I rejected the alternative hypothesis of statistically 
significant difference in the odds of developing CKD between person with normal and 
high cholesterol, normal to severely increase ACR levels, MVD or no MVD diagnosis, 
and accepted the null hypothesis of no significant odds of CKD contraction between 
person with normal and high cholesterol, normal to severely increase ACR levels, MVD 
or no MVD diagnosis. However, Table 16 showed that hypertension did significantly 
predict the odds of developing CKD among the participants while controlling for age, 
gender, smoking, and drinking (OR = 2.635, 95% CI [1.328-5.226], p< 0.05). Therefore, 
the result shows that the differences in hypertension and no hypertension were associated 
with the development of CKD. Thus, I accepted the alternative hypothesis of statistically 
significant difference in the odds of developing CKD among persons with and without 
hypertension and reject the null hypothesis of no significant odds of CKD among persons 





Summary of Binary Logistic Regression Analysis and Socioecological Model 
Variables B p value OR 95% CI 
    Lower Upper 
Cholesterol -0.101 0.730 0.904 0.509 1.606 
ACR severity 0.259 0.569 1.296 0.532 3.157 
Hypertension 
(ref = no) 
0.969 0.006 2.635 1.328 5.226 
MVD 
(ref = no) 
0.042 0.929 1.043 0.417 2.607 
Constant -1.281 0.209    
A Pearson correlation coefficient was calculated to assess the relationship 
between CKD severity and variables that could influence the severity of CKD, i.e. 
hypertension, drinking, frequency of drinking, smoking, frequency of smoking, gender, 
cholesterol, MVD and/or sickling. There was a positive correlation found between four 
variables: hypertension (r=-1.113, N= 753,p= .002), drinking (r = .139, N= 747, p<.001), 
drink frequency (r = .130, N= 671, p = .001), and smoke (r= .097,n = 747, p = .008). 
Table 17summarizes the results. Overall, there was a strong, positive correlation between 










-1.113** 0.139** 0.130** 0.097** 
 Sig. (2-tailed) 0.002 0.000 0.001 0.008 
 Number of cases 753 747 671 747 
 Pearson 
Correlation 
-1.113** 0.139** 0.130** 0.097** 
**. Correction is significant at the p<0.01 level (2-tailed). 
Summary 
I presented the results for the 2013 to 2017 Grenada medical records, to evaluate 
the relationship between MVD and CKD severity among diabetes patients with or 
without hypertension when controlling for age, AIC, BMI, gender, alcohol, and smoking 
in Grenada. A total of 998 files were reviewed, of which 770 cases were examined. I 
conducted a binary logistic regression to determine the association between CKD 
severity, the presence of hypertension, age, gender, alcohol, smoking, ACR severity and 
MVD. Drinking, age group, and history of hypertension were all significant predicators 
of CKD severity. Based on the statistical significance I accepted the null hypothesis that 
there was no association between MVD and CKD severity among diabetes patients with 
or without hypertension when controlled for AIC, BMI, gender, alcohol, ACR severity, 
and smoking in Grenada. A chi-square test was used to assess whether there was an 
association between CKD severity and the variables gender, age group, smoke, smoke 
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frequency, drinking, ACR severity, cholesterol, and MVD. An association was found 
between, age group and hypertension; therefore, I rejected the null hypothesis. In Section 
4, I discuss the findings of my research, the potential application to the practice of the 
public health profession, and implications for positive social change. 
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Section 4: Application to Professional Practice and Implications for Social Change 
Introduction 
The purpose for this quantitative, cross-sectional study was to determine if there 
is an association between MVD and CKD severity in persons with diabetes in Grenada 
who visited the Grenada General hospital with diabetes between 2013 and 2017as well as 
the prevalence of MVD. I also ascertained whether there is significance between the 
prevalence of MVD and CKD among patients with diabetes with or without hypertension 
when controlling for age, BMI, A1C, gender, alcohol use, and smoking status in Grenada. 
The key findings from the study were that smoking, drink frequency, and history of 
hypertension were significant predictors of CKD severity.  
In Section 4, I provide an interpretation of the findings as they relate to existing 
literature and the SEM. The section also includes the limitations of the study and 
recommendations for future research. Finally, I discuss the implications of the study for 
professional practice and positive social change.  
Interpretation of the Findings 
Age Group and Chronic Kidney Disease Severity 
For RQ1, I found an association between age group, hypertension, smoking, 
drinking, drink frequency, and CKD severity among persons in Grenada with diabetes. In 
this study, persons over the age of 60 years old and smoking frequency were associated 
with have a very large effect on CKD severity. These findings add to the literature 
documenting age being a contributing factor in increased risk for diseases. While age has 
been shown to impact health outcomes previously, the results from the current study may 
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be novel with a focus on health outcomes within the Caribbean and from a 
socioecological standpoint. A higher tendency for persons over the age of 60 years old to 
be at risk for CKD compared to younger persons suggests age adversely impacts health 
outcomes more than gender as it relates to CKD severity. 
Drinking and Chronic Kidney Disease Severity 
In this study, I found that drink frequency was associated with CKD severity. 
Persons who reported as never having had alcohol comprised of 78% of the study 
population, and I found a statistically significant relationship between drink frequency 
and CKD severity among this group. CKD severity was used as the constant for the 
regression analysis, with less severe patients comprising of 58% of the study population.  
The results showed that as drink frequency increased from never drinking to daily (β 
=.06, p = < .005, OR =1.801), the severity of CKD on the person increased by.06. The 
results of the current study, when compared to existing literature, also indicated that there 
is a significant association between frequency of drinking and CKD severity. In this 
study, females who drank more frequently were more likely to have increased CKD 
severity. This study may be the first to include drink frequency among female 
participants or a predominantly Black study population, whereas previous studies 
excluded drink frequency among females as it relates to CKD severity (Funakoshi et al., 
2012; Sato et al., 2014).  
Microvascular Disease and Complications of Chronic Kidney Disease 
Analysis for RQ2 indicates that although age group, smoke frequency, drink 
frequency, ACR severity, sickling, and MVD had a significant relationship with CKD 
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severity, they differed in the effect they had on CKD severity. The severity of a person’s 
CKD may be associated with number of risk factor contributors and underlining health 
conditions (i.e. sickling and/or amputations). The results for RQ2 indicated a statistically 
significant relationship between MVD, hypertension, age group, and CKD severity, 
which predicts an increased odd of having more severe CKD outcomes for older women 
(i.e., mean age of 64 years old). For MVD, there was a statistically significant difference 
of .94 with a Cohen’s d effect size of 1.04. History of hypertension was also statistically 
significant, with a mean square of1.7 and Cohen’s d effect size of .42 compared to.30 for 
those having documented cholesterol issues. A person’s age group was also statistically 
significant of p = 0.00 and a Cohen’s d effect size of 5.82, with participants 60 years old 
or older having a higher risk of more severe levels of CKD. Although vascular 
complications, prevalence, progression, and pathophysiology differ in men and women, 
the presence of diabetes among women poses a higher risk of vascular complications 
(Maric-Bilkan, 2017). Kiberd and Clase (2002) observed that among gender-race groups, 
during the lifetime of ESRD for a 20-year-old, Black women were 7.8 times more likely 
to die when compared to breast cancer among Black women. 
The results of this study were like those of Maric-Bilkan (2017) in that a 
statistically significant association was found in which women has an increased risk of 
MVD complications compared to men and, therefore, more severe forms of CKD. 
Additionally, this study finding showed the average age for women having more severe 
forms of CKD was 64 years old. The findings from the present study expound on the 
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existing literature regarding that age, in addition to gender, can be a predictor of CKD 
severity.  
The Social Ecological Model and Association Between Chronic Kidney Disease 
The theoretical framework that guided this study was SEM. This theological 
construct addresses the association between CKD risk factors, such as hypertension and 
diabetes, and addresses the complexity of socioenvironmental factors (Levey et al., 
2003). At the community level, when strategic social norm changes are facilitated with 
regards to health behavior, prescribed interventions are more effective (Golden & Earp, 
2012). The connection between delay in CKD progression and its proposed cost benefit 
to the health care system is substantial when managed effectively (Ontario Renal 
Network, 2016). The results of the study indicated that MVD, age group, and drink 
frequency were associated with increased risk of development of more severe levels of 
CKD.  
Within the medical system of the public hospital, there are currently two doctors 
to address the health needs of CKD patients. The study population demographics (N = 
775), of which only (N=165)22% of persons are currently receiving treatment within the 
Grenada, indicated that with only two specialized doctors in neuropathy available for 
limited service days, there could be a deficiency in the provision of adequate care. 
Decreased awareness of CKD and delayed referrals to nephrologists are associated with 
unsatisfactory prognosis, such as increased mortality, longer hospitalizations, and rapid 
advancement of CKD to ESRD (Smart et al., 2014). According to the theory of the SEM 
and Schroeder (2007), a key determinant in enacting social environmental change is a 
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strategic focus on the improvement of the social factors, health care, and the environment 
in order to curb persistent health inequalities.  
I used the SEM in this study to evaluate the risk factors associated with MVD and 
CKD severity not only from an individual level but for organizational structures handling 
CKD patients that affect how and how well services are provided to individuals within 
the hospital (see UNICEF, 2014). The advantage of using the SEM was that theory could 
be employed to evaluate MVD and CKD severity associations from a community level 
and could accentuate the fact that a continued dialogue is needed to address the 
organizational, social, and environmental factors contributing to CKD disparities and 
further cost-effective policy interventions are needed to shorten the disparity gap (see 
Nicholas, Kalantar-Zadeh,& Norris, 2015).  
Limitations of the Study 
I obtained the data for this study from the 2013 to 2017 medical records of the 
hospital. The study findings may be generalized to the tri-island state of Grenada, 
Carriacou, and Petite Martinique because the sample was taken from the main hospital 
that contained data from persons that are from all three islands from 2013 to 2017.The 
findings could also be used for the development of further studies on chronic diseases in 
the country. 
The sample collected provided a good representation of the health of the 
population because it included all cases for persons 16 years old and older. Though it 
does provide a good demonstration of the population, the use of a national database has 
its limitations. The classification of CKD stages was based on the National Kidney 
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Foundation’s Kidney Disease Outcomes Quality Initiative.  These diagnoses may be 
incomplete due both an absence of a common definition of CKD and misclassification of 
stage progression (Hogg et al., 2003). A notable limitation of this study was the lack of 
consistent data collection for the some of the reported fields. Another significant 
limitation of this study was the ease of accessibility to medical records. Data are only in 
paper format that required the pulling of individual patient files in order to review them 
for this study. Additionally, records did not all have the same basic data collected, (i.e., 
weight, height, blood sugar or BP); therefore, the possibility exists that there could be a 
correlation between CKD stages and BMI. 
Recommendations 
The results of this study showed that additional research is needed to identify 
interventions that can be used to improve overall outcomes of persons with MVD and/or 
CKD with a focus on improving data collection from all necessary medical staff. 
Although there have been improvements in the care of persons with kidney disease and 
MVD, not all persons have access to such care. I recommend further study of the impact 
of decreasing medical staffing has on the outcomes of persons with CKD and MVD as 
well as the financial implications to the government in order to provide a more accurate 
trajectory of these diseases on Grenada. Further studies also are needed to examine the 




Implications for Professional Practice and Social Change 
The implications of this study on public health practice include the development 
of risk assessment of MVD for both men and women. The findings of this study could be 
used by practitioners to provide age-appropriate and culturally sensitive health education 
to their patients on the risks of developing MVD and/or CKD. Sue-Hsien et al (2011) 
found that patients who actively participated in care through education not only improved 
their relationship with the clinician but also embraced CKD treatment, maximizing 
positive outcomes. Health educators, such as the health promotion team and nursing staff, 
could develop literature for the public about the risk factors that contribute to CKD and 
MVD. By having an evolving CKD education program focused on patient involvement, 
symptom management, and disability potential while emphasizing CKD risk factor 
monitoring, like hypertension and drinking habits, then both doctors and patients can 
work together to minimize or eliminate the long-term effects of CKD not only on the 
individuals but also on the community and health system.  (see Corbin & Strauss, 1991). 
The results of this study could also result in senior medical officers along with the chief 
medical officer working to develop protocols for not only efficiently tracking CKD and 
MVD cases but also conducting further studies on the long-term implications to the 
community. Finally, the findings of this study could lead to the recruitment of additional 
specialized medical staff to better assess, educate, and treat patients affected by these 
diseases. The application of these proposed interventions could lead to long-term 
reductions in CKD and MVD cases and improvement in patient outcomes. 
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Along with implications to the public health practice in Grenada, this study also 
has implications for positive social change. The observed correlations confirm the need 
for increased efforts to improve community outcomes among drinkers, those with a 
history of hypertension, and smokers to reduce the burden of CKD within society. The 
findings of this study could provide evidence for health care professionals, public health 
providers, and governmental officials to use to enhance national guidelines and change 
health policy to not only improve but reduce CKD outcomes in all tri-island members. 
The results of the study may also shed light on questions that help public health experts 
understand not only why the type of social practices and their frequency puts them at a 
higher risk of developing CKD-related complications, but also it provides the basis for 
further study to expand the global impact for the health of Black persons around the 
world. 
Conclusion 
In this study, I examined MVD and its relationship to CKD severity among 
diabetes patients with or without hypertension, when controlling for age, AIC, BMI, 
gender, and smoking. On average, older females were found to have more severe CKD 
stages (i.e., Stages 3A– 5) as compared to men. Additionally, an assessment was made to 
determine if there is a significant difference between MVD and complications of those 
with or without diabetes among men at various age groups and women at various age 
groups. 
I found a statistically significant relationship with a large effect size between age 
group, cigarette smoking status, cigarette smoking frequency, alcoholic drink frequency, 
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ACR severity, sickling, and MVD. As age increased, there was increased risk for the 
development of more severe levels of CKD among women. An increased level of CKD 
severity in women 60 years old and older compared to men, suggests that factors 
associated with gender negatively impact kidney health in women. The results of this 
study will contribute to further studies on the impact that these risk factors have on CKD 
patients’ long term as well as their impact on the community on a whole. Additionally, 
the findings of this study lay the groundwork for investment into research on other 
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